Answers are grounded in this paper and cite their sources.
Asymmetric dimethylarginine (ADMA) has been discussed as a potential biomarker of cardiovascular risk, but its interpretation in type 1 diabetes mellitus (T1DM) remains context-dependent. In commenting on the recent study by Chausheva et al., we suggest that the findings should be interpreted cautiously rather than viewed as definitively excluding clinical relevance. In addition to glycemic status, kidney function, and biological sex, ADMA concentrations may also be influenced by smoking exposure, physical inactivity, inflammatory status, and medication use. These factors may complicate its interpretation as a universal cardiovascular risk marker in heterogeneous T1DM populations. ADMA may therefore be more appropriately considered in selected phenotypes or as part of a broader multivariable framework rather than as a standalone indicator.
No takes yet. Share an insight, caveat, or question.
Can Lin (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: